vasoactive-intestinal-peptide and Glaucoma--Open-Angle

To evaluate tear neuropeptides (NPs) (vasoactive intestinal peptide (VIP), neuropeptide Y (NPY), calcitonin gene-related peptide (CGRP), substance P (SP), nerve growth factor (NGF)) in chronic ocular topical hypotensive therapy with and without benzalkonium chloride (BAK) preservative.. A comparative, open label, cross-sectional study of patients using antiglaucoma medications for. Of 153 eyes evaluated, group 1 (82 eyes (41 patients; mean age 48±14.5 years)) and group 2 (71 eyes (36 patients; mean age 43.11±15 years)) were on therapy for a mean duration of 10.05±2.0 and 9.67±2.3 months, respectively. Tear analysis showed elevated SP and NGF (p<0.01); decreased CGRP (p=0.03), VIP and NPY (p<0.01) compared with controls (n=30, mean age 29.33±5.7 years). Tear NP levels (SP (p=0.1), NGF (p=0.33), CGRP (p=1), VIP (p=0.87), NPY (p=0.83)) and SBNFL (p=0.09) were comparable in both groups. There was no correlation seen between tear NP levels and clinical tests and SBNFL.. Our study analysis points towards altered tear NP levels in eyes on chronic topical hypotensive therapy in comparison with controls with no significant difference in tear NP levels and central corneal SBNFL density between the BAK preservative and BAK-free antiglaucoma therapy.

Topics: Administration, Ophthalmic; Adolescent; Adult; Aged; Antihypertensive Agents; Benzalkonium Compounds; Calcitonin Gene-Related Peptide; Cross-Sectional Studies; Enzyme-Linked Immunosorbent Assay; Eye Proteins; Female; Glaucoma, Open-Angle; Humans; Male; Middle Aged; Nerve Growth Factor; Neuropeptide Y; Neuropeptides; Ophthalmic Solutions; Preservatives, Pharmaceutical; Prospective Studies; Substance P; Tears; Vasoactive Intestinal Peptide; Young Adult